银屑病生物制剂治疗对结核感染的影响及机制

doi:10.35541/cjd.20210672

Abstract

Abstract: 【Abstract】 In recent years, biological agents have played an active role in the treatment of psoriasis, especially for severe, refractory and special subtypes of psoriasis. However, their safety has attracted increasing attention, especially the risk of tuberculosis infection. This review summarizes the effect of biological agents with different targets on tuberculosis infection and relevant mechanisms, aiming to provide a theoretical basis for psoriasis patients to choose appropriate biotherapy.

Key words: Psoriasis, Biological agents, Tuberculosis, Latent tuberculosis, Biotherapy

Tang Zijie, Wang Rui, Li Chengxin. Effect of biotherapy for psoriasis on tuberculosis infection and relevant mechanisms[J]. Chinese Journal of Dermatology, 2024, 57(10): 959-962.doi:10.35541/cjd.20210672

References ［31］

［1］	Gupta N, Kumar R, Agrawal B. New players in immunity to tuberculosis: the host microbiome, lung epithelium, and innate immune cells［J］. Front Immunol, 2018,9:709. doi: 10.3389/fimmu.2018.00709.
［2］	Evangelatos G, Koulouri V, Iliopoulos A, et al. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors［J］. Ther Adv Musculoskelet Dis, 2020,12:1759720X20930116. doi: 10.1177/1759720X20930116.
［3］	Domingo⁃Gonzalez R, Prince O, Cooper A, et al. Cytokines and chemokines in Mycobacterium tuberculosis infection［J］. Microbiol Spectr, 2016,4（5）: 10.1128/microbiolspec.TBTB2⁃0018⁃2016. doi: 10.1128/microbiolspec.TBTB2⁃0018⁃2016.
［4］	Cantini F, Nannini C, Niccoli L, et al. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non⁃anti⁃TNF⁃targeted biologics［J］. Mediators Inflamm, 2017,2017:8909834. doi: 10.1155/2017/8909834.
［5］	Griffiths Christopher EM, Armstrong April W, Gudjonsson Johann E, et al. Psoriasis［J］. Lancet, 2021,397:1301⁃1315. doi: 10. 1016/S0140⁃6736（20）32549⁃6.
［6］	肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识［J］. 中华风湿病学杂志, 2013,17（8）:508⁃512. doi: 10.3760/cma.j.issn.1007⁃7480.2013.08.002.
［7］	Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion［J］. Cell Mol Immunol, 2017,14（12）:963⁃975. doi: 10.1038/cmi.2017.88.
［8］	Stutz MD, Allison CC, Ojaimi S, et al. Macrophage and neutrophil death programs differentially confer resistance to tuberculosis［J］. Immunity, 2021,54（8）:1758⁃1771.e7. doi: 10.1016/j.immuni. 2021.06.009.
［9］	Dobler CC. Biologic agents and tuberculosis［J］. Microbiol Spectr, 2016,4（6）:10.1128/microbiolspec.TNMI7⁃0026⁃2016. doi: 10.1128/microbiolspec.TNMI7⁃0026⁃2016.
［10］	Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts（ESGICH） Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective（Soluble immune effector molecules ［I］: anti⁃tumor necrosis factor⁃α agents）［J］. Clin Microbiol Infect, 2018,24（Suppl 2）:S10⁃S20. doi: 10.1016/j.cmi.2017.12.025.
［11］	Goel N, Torralba K, Downey C, et al. Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California［J］. Clin Rheumatol, 2020,39（8）:2291⁃2297. doi: 10.1007/s10067⁃020⁃04991⁃y.
［12］	Fallahi⁃Sichani M, Flynn JL, Linderman JJ, et al. Differential risk of tuberculosis reactivation among anti⁃TNF therapies is due to drug binding kinetics and permeability［J］. J Immunol, 2012,188（7）:3169⁃3178. doi: 10.4049/jimmunol.1103298.
［13］	Floss DM, Moll JM, Scheller J. IL⁃12 and IL⁃23⁃close relatives with structural homologies but distinct immunological functions［J］. Cells, 2020,9（10）:2184. doi: 10.3390/cells9102184.
［14］	López⁃Ferrer A, Laiz A, Puig L. The safety of ustekinumab for the treatment of psoriatic arthritis［J］. Expert Opin Drug Saf, 2017,16（6）:733⁃742. doi: 10.1080/14740338.2017.1323864.
［15］	Jung SW, Lim SH, Jeon JJ, et al. Comparison of the efficacy and safety of biologics（secukinumab, ustekinumab, and guselkumab） for the treatment of moderate⁃to⁃severe psoriasis: real⁃world data from a single korean center［J］. Biomedicines, 2022,10（5）:1058. doi: 10.3390/biomedicines10051058.
［16］	Kaneko S, Tsuruta N, Yamaguchi K, et al. Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: real⁃world data from 18 Japanese facilities［J］. J Dermatol, 2020,47（2）:128⁃132. doi: 10.1111/1346⁃8138.15156.
［17］	Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double⁃blind, placebo⁃controlled, phase 2 study［J］. Lancet, 2018,391（10136）:2213⁃2224. doi: 10.1016/S0140⁃6736（18）30952⁃8.
［18］	Crowley JJ, Warren RB, Cather JC. Safety of selective IL⁃23p19 inhibitors for the treatment of psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1676⁃1684. doi: 10.1111/jdv.15653.
［19］	Reich K, Warren RB, Iversen L, et al. Long⁃term efficacy and safety of tildrakizumab for moderate⁃to⁃severe psoriasis: pooled analyses of two randomized phase III clinical trials（reSURFACE 1 and reSURFACE 2） through 148 weeks［J］. Br J Dermatol, 2020,182（3）:605⁃617. doi: 10.1111/bjd.18232.
［20］	Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate⁃to⁃severe plaque psoriasis: pooled analysis of three randomized controlled trials［J］. Br J Dermatol, 2018,179（3）:615⁃622. doi: 10.1111/bjd.16724.
［21］	Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate⁃to⁃severe plaque psoriasis（IMMvent）: a randomised, double⁃blind, active⁃comparator⁃controlled phase 3 trial［J］. Lancet, 2019,394（10198）:576⁃586. doi: 10.1016/S0140⁃6736（19）30952⁃3.
［22］	Torrado E, Cooper AM. IL⁃17 and Th17 cells in tuberculosis［J］. Cytokine Growth Factor Rev, 2010,21（6）:455⁃462. doi: 10.1016/j.cytogfr.2010.10.004.
［23］	Kammüller M, Tsai TF, Griffiths CE, et al. Inhibition of IL⁃17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections［J］. Clin Transl Immunology, 2017,6（8）:e152. doi: 10.1038/cti.2017.34.
［24］	Segueni N, Tritto E, Bourigault ML, et al. Controlled Mycobacterium tuberculosis infection in mice under treatment with anti⁃IL⁃17A or IL⁃17F antibodies, in contrast to TNFα neutralization［J］. Sci Rep, 2016,6:36923. doi: 10.1038/srep36923.
［25］	Blauvelt A, Lebwohl MG, Bissonnette R. IL⁃23/IL⁃17A dysfunction phenotypes inform possible clinical effects from anti⁃IL⁃17A therapies［J］. J Invest Dermatol, 2015,135（8）:1946⁃1953. doi: 10.1038/jid.2015.144.
［26］	Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate⁃to⁃severe psoriasis through 5 years of treatment（SCULPTURE Extension Study）［J］. J Eur Acad Dermatol Venereol, 2018,32（9）:1507⁃1514. doi: 10.1111/jdv.14878.
［27］	Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate⁃to⁃severe plaque psoriasis: a multi⁃center, retrospective, real⁃life study up to 52 weeks observation［J］. Expert Opin Biol Ther, 2018,18（7）:727⁃735. doi: 10.1080/14712598.2018.1481503.
［28］	Fowler E, Ghamrawi RI, Ghiam N, et al. Risk of tuberculosis reactivation during interleukin⁃17 inhibitor therapy for psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1449⁃1456. doi: 10.1111/jdv.16254.
［29］	Romiti R, Valenzuela F, Chouela EN, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis［J］. Br J Dermatol, 2019,181（1）:202⁃203. doi: 10.1111/bjd.17604.
［30］	Mrowietz U, Riedl E, Winkler S, et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: a report from 16 clinical studies of patients with psoriasis or psoriatic arthritis［J］. J Am Acad Dermatol, 2020,83（5）:1436⁃1439. doi: 10.1016/j.jaad.2020.06. 012.
［31］	Kelsey A, Chirch LM, Payette MJ. Tuberculosis and interleukin blocking monoclonal antibodies: is there risk?［J］. Dermatol Online J, 2018,24（9）:13030/qt58j4n38m.

[1]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[2]	Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742.
[3]	Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769.
[4]	Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2024, 57(6): 570-574.
[5]	Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444.
[6]	Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 426-434.
[7]	China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417.
[8]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China （2024） [J]. Chinese Journal of Dermatology, 2024, 0(5): 20240294-e20240294.
[9]	Working Group on “Expert consensus on clinical use of secukinumab in the treatment of psoriasis”. Expert consensus on clinical use of secukinumab in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(5): 20240226-e20240226.
[10]	Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475.
[11]	Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478.
[12]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482.
[13]	Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429.
[14]	Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358.
[15]	Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378.

Effect of biotherapy for psoriasis on tuberculosis infection and relevant mechanisms

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［31］

Related Articles 15

Metrics

Comments

Recommended 10